Doxiadis I I, Witvliet M, Verduyn W, de Lange P, Tanke J, Schreuder G M, Persijn G G, Claas F H
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Clin Transpl. 2000:99-103.
Organ exchange organizations such as Eurotransplant allocate organs on the basis of histocompatibility testing results. For this reason it is essential that all data reported by the affiliated laboratories are accurate and reliable. The Eurotransplant Reference Laboratory (ETRL) organizes proficiency testing schemes for the tissue-typing centers of the respective renal transplantation units participating in Eurotransplant. Each year, the ETRL sends out 8 peripheral blood samples of healthy blood donors for serological typing and crossmatching, 16 sera to screen for the presence and definition of HLA alloantibodies and 20 DNA samples for molecular typing to the 49 participating centers. The results are collected centrally and reported back to the participants in an open way. These exercises show that the quality of HLA typing, screening and crossmatching improved significantly over the years. In particular, the introduction of molecular typing for HLA-DR resulted in an increase of reliability. The clinical relevance of a reliable HLA typing was demonstrated in a selected group of transplants, the zero HLA-A,-B,-DR- mismatched group. After retyping the donors, 146 of the 3,458 matched transplants appeared to have a mismatch and those transplants had a significantly lower graft survival rate. A continuing problem, however, is the result of screening for panel reactive antibodies (PRA), where the percentage PRA reported for each serum varies significantly from center to center. The results indicate that the use of a PRA value for classification of patients and allocation of organs should be revisited.
诸如欧洲器官移植组织(Eurotransplant)这样的器官交换组织会根据组织相容性检测结果来分配器官。因此,附属实验室报告的所有数据准确可靠至关重要。欧洲器官移植参考实验室(ETRL)为参与欧洲器官移植的各个肾移植单位的组织配型中心组织能力验证计划。每年,ETRL会向49个参与中心发送8份健康献血者的外周血样本用于血清学配型和交叉配型,16份血清用于筛查HLA同种抗体的存在及鉴定,以及20份DNA样本用于分子配型。结果集中收集并以公开方式反馈给参与者。这些活动表明,多年来HLA配型、筛查和交叉配型的质量有了显著提高。特别是,HLA-DR分子配型的引入提高了可靠性。在一组选定的移植手术中,即HLA-A、-B、-DR零错配组,证明了可靠的HLA配型的临床相关性。在对供体重新配型后,3458例配型移植手术中有146例出现错配,这些移植手术的移植物存活率明显较低。然而,一个持续存在的问题是群体反应性抗体(PRA)筛查的结果,各中心报告的每份血清的PRA百分比差异很大。结果表明,应重新审视使用PRA值对患者进行分类和分配器官的做法。